Evidence map›Paper›PMID 27655725›Full record

SynthesisOncotarget2016

Management of advanced gastric cancer: An overview of major findings from meta-analysis.

Xiaolong Qi, Yanna Liu, Wei Wang, Danxian Cai, Wende Li, Jialiang Hui, Chuan Liu, Yanxia Zhao, Guoxin Li

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Circ_0008035 Promotes Gastric Cancer Development via the miR-429/SMAD2 Cascade.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024
    Article
  4. Article
  5. Article
  6. Circular RNAs as important players in human gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaolong QiDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yanna LiuDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wei WangDepartment of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Danxian CaiDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wende LiGuangdong Laboratory Animal Monitoring Institute, Guangzhou, China.
Jialiang HuiDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Chuan LiuDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yanxia ZhaoCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Guoxin LiDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to provide an overview of different treatment for advanced gastric cancer. In the present study, we systematically reviewed the major findings from relevant meta-analyses. A total of 54 relevant papers were searched via the PubMed, Web of Science, and Google scholar databases. They were classified according to the mainstay treatment modalities such as surgery, chemotherapy and others. Primary outcomes including overall survival, response rate, disease-free survival, recurrence-free survival, progression-free survival, time-to-progression, time-to failure, recurrence and safety were summarized. The recommendations and uncertainties regarding the treatment of advanced gastric cancer were also proposed. It was suggested that laparoscopic gastrectomy was a safe and technical alternative to open gastrectomy. Besides, neoadjuvant chemotherapy and adjuvant chemotherapy were thought to benefit the survival over surgery alone. And it was demonstrated in the study that targeted therapy like anti-angiogenic and anti-HER2 agents but anti-EGFR agent might have a significant survival benefit.

Indexed as

Chemotherapy, AdjuvantDisease-Free SurvivalHumansStomach Neoplasmsadvanced gastric cancerchemotherapymanagementmeta-analysissurgery

Identifiers

PMID27655725
PMCPMC5363654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.